Scalable manufacturing platform for purification of viral vectors and purified viral vectors in this way for use in gene therapy

Method for purifying vector particles adeno-associated virus (AAV) genuine comprising a transgene encoding a therapeutic protein or fragment thereof from a preparation of AAV comprising particles of AAV vector, empty capsids and impurities host cell, said method comprising: a) collecting cells and cell supernatant comprising AAV particles; b) concentrating said cells and said supernatant by tangential flow filtration c) lysing said cells by microfluidization to form a lysate; d) filtering, thereby clarifying the lysate of step c); e) purifying AAV particles comprising particles of AAV vector genuine by column chromatography to produce ion exchange eluate, and then optionally concentrating the eluate from the column by tangential flow filtration; f) mixing said eluate with cesium chloride and subjecting said mixture to gradient ultracentrifugation to separate AAV vectors related impurities genuine AAV vector; g) collecting particles that comprise AAV vector particles genuine VAA separated in step f) and subjecting the same to a buffer exchange by tangential flow filtration; h) formulating said particles comprise AAV vector particles genuine VAA step g) surfactant to provide a formulation of AAV particles; i) filtering said formulation of step h) to remove the remaining impurities, wherein said vector particles are present in genuine VAA the resulting filtrate in an amount of at least 90%.